Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B

Trial Profile

Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Adverse reactions
  • Acronyms FROSTY
  • Sponsors Aviragen Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top